LIST OF PUBLICATIONS FROM THE NORDIC LYMPHOMA GROUP 1999 - 2003:

1.       Jerkeman M, Johansson B, Akerman M, Cavallin-Stahl E, Kristoffersson U, Mitelman F. Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999 Mar;62(3):184-90.

2.       Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaloy S, Sundstrom C, Akerman M. CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol. 1999 Sep;10(9):1079-86.

3.       Rodriguez-Catarino M, Jerkeman M, Ahlstrom H, Glimelius B, Hagberg H. Residual mass in aggressive lymphoma--does size, measured by computed tomography, influence clinical outcome? Acta Oncol. 2000;39(4):485-9.

4.       Amini RM, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E and Glimelius B. Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. Eur J Haematol 65:379-89 (2000).

5.       Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol. 2001;18(1):85-94.

6.       Osby E, Taube A, Cavallin-Stahl E, Hagberg H, Bjorkholm M. Reproducibility of tumor response e-valuation in patients with high-grade malignant non-Hodgkin's lymphoma. Med Oncol. 2001;18(2):137-40.

7.       Amini R-M, Glimelius B, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Enblad G. A population-based study of the outcome for patients with first relapse of Hodgkin’s lymphoma. Eur J Haematol 68:225-232 (2002).

8.       Jerkeman M, Aman P, Cavallin-Stahl E, Torlakovic E, Akerman M, Mitelman F, Fioretos T. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Int J Oncol. 2002 Jan;20(1):161-5.

9.       Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP Br J Cancer 2001;84:303-7.

10.    Goldkuhl C, Ekman T, Wiklund T, Telhaug R. Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study. Acta Oncol. 2002;41(1):29-35.

11.    Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Bjorkholm M. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group Randomized trial. Blood. 2003 Jan 16

12.    Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study. Clin Cancer Res. 2003 Feb;9(2):722-8.

13.    Molin D, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Glimelius B. Early and intermediate stage Hodgkin’s lymphoma – report from the Swedish National Care Programme. Eur J Haematol 70:172-80 (2003).

14.    Andersen NS, Pedersen, Elonen E et al for the Nordic Lymphoma Group. Primary Treatment with autologous stem cell transplantation in Mantle Cell Lymphoma. Outcome related to remission pretransplant but not to tumour cell contamination of the autograft. Eur J Haematol, In Press.